Julie M Collins

4PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Filipa Lynce, Candace Mainor, Renee N Donahue

|Mar 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Filipa Lynce, Candace Mainor, Renee N Donahue

|Jul 12, 2020
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.

Julie M Collins, Claudine Isaacs

|Nov 28, 2018
Product review: avelumab, an anti-PD-L1 antibody.

Julie M Collins, James L Gulley

Pageof 1

Frequent Collaborators

3 joint publications

Claudine Isaacs

2 joint publications

Filipa Lynce

2 joint publications

Candace Mainor

2 joint publications

Renee N Donahue